A prolyl oligopeptidase inhibitor, KYP-2047, reduces ?-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease - rPeptide

Skip to content

Products
Services
Resources
About
Sign In

Search for:

Sign In
$0.00 0

Products
Services
Resources
About

Search for:

Antibodies

Beta-Amyloid Antibodies
Synuclein
Tau

Peptides

Amylin
Amyloid Precursor Protein Related Peptide
Beta-Amyloid

Proteins

Apolipoprotein
Chemokine
Calmodulin
Human Plasma Proteins
Surfactants
Synuclein
Tau
Tubulin

Neurodegenerative Related Compounds Coronavirus Research Tools

COVID-19/ Sars-Cov-2 Related Compounds
COVID-19/ Sars-Cov-2 Related Proteins

Kits

Beta-Amyloid
Tau

Preformed Fibrils

Beta-Amyloid Preformed Fibrils
Synuclein Preformed Fibrils
Tau Preformed Fibrils

Custom Peptides & Proteins
Lab Services
Bulk Quote
Amino Acid Codes

Citations
Industry News
International Distributors
FAQs
Ordering Overview
Terms of Use

Our Company
ISO Certificate
Quality Manual
Contact Information

News

May 7, 2012
Wiley Online Library:A prolyl oligopeptidase inhibitor, KYP-2047, reduces ?-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease A prolyl oligopeptidase inhibitor, KYP-2047, reduces ?-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease

View all news

Products
Antibodies
Peptides
Proteins
Neurodegenerative Related Compounds
Coronavirus Research Tools
Kits
Preformed Fibrils

Services
Custom Peptides & Proteins
Lab Services
Bulk Quote
Amino Acid Codes

Resources
Citations
Industry News
International Distributors
FAQs
Ordering Overview
Terms of Use

About
Our Company
ISO Certificate
Quality Manual
Contact Information

rPeptide

ph: 866.753.0747 fax: 678.753.0746 e: sales@rpeptide.com

Follow Us

Newsletter Signup

© 2025

rPeptide Sitemap | Privacy | Terms & Conditions

rPeptide products are for research purposes only. Not for human consumption.

Cleantalk Pixel